Close Menu
October 07, 2019
Sponsored by
Thermo Fisher Scientific

Future-Proofing a Genomics Core: Considerations When Adopting New NGS Technologies


This webinar provides an overview of the sequencing capabilities of the Tumor Profiling Unit at the Institute for Cancer Research in London, with a focus on the lab's strategy for bringing in new genomics technologies.

Improvements in next-generation sequencing technology have historically focused on speed and throughput, while the latest advances are focused on data quality and sensitivity of detection. Adopting new technologies that offer greater genomic insights will bring current genomic labs gracefully into 2020 and beyond.

In this webinar, Nik Matthews, manager of the ICR Tumor Profiling unit, shares insight into the current state of NGS technology and considerations to remain at the forefront of improvements in data quality.


Sponsored by

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Sponsored by
10x Genomics

This webinar will discuss a study that combined single-cell gene expression and spatial gene expression to understand the evolution of sepsis in the kidney at the cellular and molecular level.

Sponsored by

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics.